Lp(a) is a genetically-driven and independent risk factor for CVD with no approved treatments. Lilly is advancing muvalaplin and has some good competition.
Mary Caffrey
Advertisement
Articles by Mary Caffrey
A new analysis found triple therapy for COPD, particularly B/G/F, more cost-effective vs dual therapy in terms of exacerbations and quality-adjusted life years.
The pair of scientists was cited "for their discoveries concerning nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19."
Atrial fibrillation prevalence is rising across socioeconomic strata globally, the new analysis finds, with effects of BMI, ETOH, and sedentary behavior shifting as key drivers.
Oldest and most frail elderly were at more than 60% greater risk of bleeding when switched from a VKA than those who remained on the traditional agent.
Advertisement
Latest Updated Articles
Worldwide Burden of Atrial Fibrillation More Than Doubled Over 30 Years: Global AnalysisPublished: September 1st 2023 | Updated:
Nobel Prize Awarded to Scientists Whose Work on mRNA Led to Development of COVID-19 VaccinesPublished: October 3rd 2023 | Updated:
Frail Elderly at High Risk of Bleeding Following VKA-DOAC Switch: Surprise Outcome Shared at ESC CongressPublished: August 28th 2023 | Updated:
Budesonide-Based Triple Therapy Most Cost-Effective vs Dual Therapy for COPDPublished: May 9th 2024 | Updated:
Advertisement
Advertisement
Trending on Patient Care Online
1
New Menopause Survey Finds Energy Loss, Poor Sleep, and Seasonal Symptoms Most Disruptive
2
The Adult Immunization Catch-Up Schedule: A Practical Guide for Primary Care
3
Survey Finds Semaglutide Eases Food-Related Intrusive Thoughts, Boosts Mental Health: Daily Dose
4
Undertreated Acute Pain Poses Long-Term Risks, But Prescription Opioids Still Do, Too ...
5
